Inhibitor Therapeutics Inc is a pharmaceutical development company that is focused on developing and ultimately commercializing therapeutics based on already approved active pharmaceuticals that have patent-protected methods of use and/or methods of delivery for patients with certain cancers and certain non-cancerous proliferation disorders... Show more
Industry Biotechnology
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| RLIEX | 17.01 | 0.12 | +0.71% |
| Lazard International Equity R6 | |||
| AEPCX | 51.54 | 0.22 | +0.43% |
| American Funds Europacific Growth C | |||
| AASSX | 18.55 | N/A | N/A |
| American Beacon Small Cp Val Adv | |||
| STRSX | 24.38 | N/A | N/A |
| Sterling Capital Special Opps R6 | |||
| DSHZX | 11.02 | N/A | N/A |
| Brinker Capital Destinations Shelter Z | |||
A.I.dvisor tells us that INTI and QRON have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that INTI and QRON's prices will move in lockstep.
| Ticker / NAME | Correlation To INTI | 1D Price Change % | ||
|---|---|---|---|---|
| INTI | 100% | -15.54% | ||
| QRON - INTI | 24% Poorly correlated | N/A | ||
| DWTX - INTI | 23% Poorly correlated | +14.48% | ||
| IVEVF - INTI | 17% Poorly correlated | N/A | ||
| IVBXF - INTI | 11% Poorly correlated | +2.90% | ||
| HSTC - INTI | 8% Poorly correlated | +4.41% | ||
More | ||||